Fibromyalgia Diagnosis via Nucleic Acid Expression Signatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for fibromyalgia lack precision and accuracy, with no individual biomarkers available for reliable diagnosis, leading to challenges in clinical assessment and differential diagnosis from other conditions like rheumatoid arthritis and systemic lupus erythematosus.
Innovation Solution
A method involving the measurement of nucleic acid expression levels of specific biomarkers using techniques like qRT-PCR, RNAseq, or whole transcriptome analysis, comparing these levels to control samples to classify subjects as having fibromyalgia, utilizing statistical algorithms for correlation analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (physical examination, tender points assessment) are used for fibromyalgia diagnosis, then the assessment can be performed without complex equipment, but the precision and accuracy of diagnosis is insufficient
Solution Approach 1:
The invention shifts from physical assessment parameters (tender point count, pain scale) to molecular biological parameters (gene expression levels, protein markers). By measuring expression levels of specific genes and proteins in blood samples, the diagnostic precision is significantly improved while the complexity remains manageable through standardized laboratory assays.
Solution Approach 2:
The invention replaces the mechanical/physical examination system (manual tender point palpation, clinical assessment) with a biochemical measurement system (molecular assays, gene expression analysis). This substitution enables objective, quantifiable measurements that provide superior diagnostic accuracy compared to subjective physical assessments.
2Reliability
If no individual biomarkers are used for fibromyalgia diagnosis, then the diagnostic approach remains simple and broad, but the reliability and accuracy of diagnosis deteriorates
Solution Approach 1:
The invention segments the diagnostic process by identifying and measuring specific individual biomarkers (gene expression markers, protein markers) rather than relying on overall clinical assessment. Each biomarker provides discrete, independent information that contributes to the overall diagnostic reliability, allowing for targeted and specific diagnosis.
Solution Approach 2:
The invention introduces molecular biomarkers as intermediary substances that mediate between the disease state and the diagnostic measurement. These biomarkers (specific genes, proteins in blood) serve as measurable intermediaries that reflect the underlying pathophysiology of fibromyalgia, enabling reliable indirect assessment of the condition.
3Adaptability or versatility
If clinical criteria (tender points, widespread pain assessment) are used for diagnosis, then the diagnostic method can be applied widely without specialized equipment, but the ability to differentiate from other conditions (rheumatoid arthritis, lupus) deteriorates
Solution Approach 1:
The invention applies local quality by identifying fibromyalgia-specific biomarker profiles that are unique to this condition. Rather than using general pain assessment criteria, the method measures specific gene expression patterns and protein markers that are locally characteristic of fibromyalgia pathophysiology, enabling precise differentiation from other rheumatic conditions.
Solution Approach 2:
The invention inverts the traditional diagnostic approach by instead of asking 'does the patient meet clinical criteria?', it asks 'does the patient exhibit the fibromyalgia molecular signature?'. This inversion shifts from phenotype-based diagnosis to genotype/molecular phenotype-based diagnosis, providing superior differential diagnostic capability.
Data Source
AI summary
The invention provides methods for detecting or diagnosing fibromyalgia (FM) in an individual by determining the expression of biomarkers at the nucleic acid level. Also provided herein are methods for detecting or diagnosing FM in an individual and using said detection or diagnosis to guide administration of treatments for said conditions.